Ptc Therapeutics, Inc.

Silamed, Inc.

Stephen P Wanaski

Stephen Gately

Virginia D Schmith

Scott Joseph Brantley

Linda L Grasfeder

The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor.

Methods of administering deflazacort therapy

Novel compositions of silicon-substituted carboxylic acid-containing-nonsteroidal anti-inflammatory drugs, their preparation and use in methods for treating, preventing and/or reducing inflammation, pain, angiogenesis, and cortical dementias including Alzheimer's disease, inflammation-related cardiovascular disorders and cancer are described. The compositions and methods are effective at decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of non-selective carboxylate-containing-nonsteroidal anti-inflammatory drugs.

Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives

Growing community of inventors

Chicago, IL, United States of America

Stephen P Wanaski